Background: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods: 7.2 million cancer patients (42 population-based cancer registries in 17 European coun- tries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5dataset. Mixture-curemodelswereusedtoestimate:(i)lifeexpectancyoffatalcases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general popula- tion; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results: LEF ranged from 10years for chronic lymphocytic leukaemia patients to <6months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7years for patients with prostate cancer at age 65-74years and >5years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for pros- tate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thy- roid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorec- tal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. Conclusions: Estimates from this analysis should help to reduce unneeded medicaliza- tion and costs. They represent an opportunity to improve patients' quality of life.
Cancer cure for 32 cancer types: results from the EUROCARE-5 study
2020
Abstract
Background: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods: 7.2 million cancer patients (42 population-based cancer registries in 17 European coun- tries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5dataset. Mixture-curemodelswereusedtoestimate:(i)lifeexpectancyoffatalcases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general popula- tion; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results: LEF ranged from 10years for chronic lymphocytic leukaemia patients to <6months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7years for patients with prostate cancer at age 65-74years and >5years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for pros- tate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thy- roid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorec- tal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. Conclusions: Estimates from this analysis should help to reduce unneeded medicaliza- tion and costs. They represent an opportunity to improve patients' quality of life.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
